The Drug Enforcement Administration (DEA) announced last Friday that certain Food and Drug Administration (FDA)-approved drugs that contain cannabidiol (CBD) are properly rescheduled as Schedule V drugs under the Controlled Substances Act (CSA). While this move is far from categorically rescheduling CBD – as only...
I. Background Recently, we reported on the current state of hemp and CBD laws in the United States following the Ninth Circuit’s April 2018 decision in HIA v. DEA (Case No. 17-70162), the proposed Hemp Farming Act of 2018 (S. 2667), and reading through to...
By: Sam Mendez, Strategic Legal Counsel at Cultiva Law Cannabis policy and politics continue to evolve on both state and federal levels and, in the Trump era, it is not uncommon to experience unexpected and even conflicting developments. Conservative Republican former Speaker of the House John Boehner joins a...
An Analysis of Hemp Industries Association, et al. v. U.S. Drug Enforcement Administration (Case No. 17-70162) and the Hemp Farming Act of 2018 (S. 2667) I. Hemp Industries Ass’n. v. DEA (April 30, 2018) The Ninth Circuit Court of Appeals issued its decision in Hemp Industries Association,...